ClinicalTrials.Veeva
Menu

Find clinical trials for Glioblastoma (GBM) in Ann Arbor, MI

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Glioblastoma
Recurrence
Glioma
Brain Cancer
Astrocytoma
Cancer
Gliosarcoma

Glioblastoma (GBM) trials near Ann Arbor, MI, USA:

INO-5401 and INO-9012 Delivered by Electroporation (EP) in Combination With Cemiplimab (REGN2810) in Newly-Diagnosed Glioblastoma (GBM)

efficacy of INO-5401 and INO-9012 in combination with cemiplimab (REGN2810), with radiation and chemotherapy, in subjects with newly-diagnosed glioblastoma...

Active, not recruiting
Glioblastoma
Drug: Temozolomide
Biological: INO-9012

Phase 1, Phase 2

Inovio Pharmaceuticals
Inovio Pharmaceuticals

Detroit, Michigan, United States and 20 other locations

In summary, standard of care postoperative chemoradiation for patients with newly diagnosed GBM does not routinely provide durable local con...

Enrolling
Glioblastoma
Device: Surgical tumor resection, GammaTile radiation therapy implantation, Stupp protocol (EBRT and Temozolamide)

Phase 4

GT Medical Technologies

Detroit, Michigan, United States and 15 other locations

Glioblastoma (GBM) adaptive, global, innovative learning environment (GBM AGILE) is an international, seamless Phase II/II....

Enrolling
Glioblastoma
Drug: Temozolomide
Radiation: Radiation

Phase 2, Phase 3

Global Coalition for Adaptive Research

Detroit, Michigan, United States and 61 other locations

OKN-007 combined with temozolomide(TMZ) in patients with recurrent glioblastoma(GBM). All patients will have been previously treate...

Active, not recruiting
Brain Glioblastoma
Recurrent Malignant Glioma
Drug: Temozolomide (TMZ)
Drug: OKN-007

Phase 2

Oblato

Detroit, Michigan, United States and 12 other locations

The purpose of this study is to assess progression-free survival (PFS) and overall survival (OS) in newly diagnosed Glioblastoma (GBM...

Active, not recruiting
Glioblastoma
Combination Product: IGV-001 Cell Immunotherapy
Drug: SOC: Temozolomide

Phase 2

Imvax

Detroit, Michigan, United States and 22 other locations

To test the effectiveness and safety of Optune® given concomitantly with radiation therapy (RT) and temozolomide (TMZ) in newly diagnosed GBM...

Active, not recruiting
Glioblastoma Multiforme
Device: Optune®
NovoCure
NovoCure

Ann Arbor, Michigan, United States and 132 other locations

The purpose of this study is to establish the recommended phase 2 dose of eflornithine in combination with temozolomide in patients whose glioblastoma...

Enrolling
Glioblastoma
Glioblastoma Multiforme
Drug: Temozolomide
Drug: Eflornithine (Dose Level 2)

Phase 1

Orbus Therapeutics

Detroit, Michigan, United States and 7 other locations

* To evaluate the safety and tolerability of escalating doses of ERAS-801 in study participants with recurrent glioblastoma multiforme (GBM...

Active, not recruiting
Glioblastoma Multiforme
Drug: ERAS-801

Phase 1

Erasca

Detroit, Michigan, United States and 7 other locations

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems